By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-08.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-08.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-08.
A physician-reviewed guide to what actually drives low sexual desire in women — hormones, medications, health, relationships — and how a clinician evaluates it.
A physician-reviewed guide to what actually drives low sexual desire in women — hormones, medications, health, relationships — and how a clinician evaluates it.
A physician-reviewed guide to what actually drives low sexual desire in women — hormones, medications, health, relationships — and how a clinician evaluates it.
When Desire Fades: How a Clinician Sorts Out What's Actually Behind Low Libido in Women
When Desire Fades: How a Clinician Sorts Out What's Actually Behind Low Libido in Women
Sexual health (women's)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Sexual health (women's)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Sexual health (women's)
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Key takeaways
Low sexual desire is the most common sexual concern women report, and when it causes distress it is a recognized, evaluable condition — not a character flaw or an inevitable part of aging.
In most cases there is an identifiable contributor, or several: hormonal shifts, thyroid or other medical conditions, medications (antidepressants are a frequent and reversible cause), pain, sleep, mood, and relationship factors all interact.
Because the cause guides the fix, an evaluation comes before any therapy. The evidence-based options — including bremelanotide, which is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and low-dose testosterone in the postmenopausal HSDD context — each fit a specific picture, not everyone.
The practical takeaway: low desire is worth a real workup. A physician who checks labs and reviews your health and medications can usually explain what changed — and what, if anything, is worth doing about it.
If your interest in sex has faded and you cannot point to a single reason, the most useful thing to know first is this: low desire in women is common, it is usually explainable, and when it bothers you it is treatable. It is the sexual concern women report most — and when it comes with genuine distress, clinicians recognize it as a specific condition. The unhelpful part is how often it gets waved off. The useful question is not how to want it more, but what actually changed.
If you have raised this with a clinician and been told to "relax," "have a glass of wine," or "try date night," that experience is real and it is common. Those answers skip the step that matters — finding the cause. What follows is how a physician actually sorts through it.
Low Desire Is Common — and It Is a Recognized Condition
The biological and epidemiological picture is clear. In the PRESIDE study, a survey of more than 31,000 U.S. women, low desire was the single most common sexual problem, reported by roughly 38% of women; when low desire caused personal distress, it met the threshold for hypoactive sexual desire disorder (HSDD) in about 10% overall and close to 9% of women aged 18–44 (Shifren 2008, PMID: 19008846). In other words, this is not rare, and it is not a fringe complaint.
The word that does the work in that definition is distress. Desire varies enormously between people and across a lifetime, and lower desire by itself is not a disorder. What makes it a clinical issue is that it bothers you — it interferes with how you feel about yourself or your relationship. Naming it precisely matters, because a recognized condition has an evaluation pathway and evidence-based options, where a dismissed complaint has neither; the ISSWSH process of care lays out exactly that evaluation pathway (Clayton 2018). If a provider treats low desire as something to simply accept, that is information about the provider, not about whether the concern is real.
The Differential: What a Clinician Actually Checks
Desire is not a single switch. It emerges from hormones, brain chemistry, physical comfort, mood, sleep, and the relationship it lives in — which is exactly why an honest evaluation looks at several systems rather than reaching for one answer. The most common contributors:
Hormones and thyroid. Estrogen and testosterone both play a role in women's desire, and thyroid disease and elevated prolactin can blunt it; iron deficiency can contribute as well, often through the fatigue it causes. A panel that reads these together — rather than a single number — is the point.
Medications. This is the most frequently missed reversible cause. Selective serotonin reuptake inhibitors (SSRIs) and some other antidepressants commonly lower desire and delay arousal; certain hormonal contraceptives and other drugs can contribute too. Often the fix is an adjustment, a switch, or an added medication — not accepting the side effect.
Pain and the genitourinary changes of menopause. When sex is uncomfortable, desire follows the discomfort down. Vaginal dryness and tissue thinning — the genitourinary syndrome of menopause — are common, under-reported, and treatable, often with local therapy.
Sleep, stress, and mood. Chronic sleep loss and untreated depression or anxiety suppress desire directly and through fatigue. Depression and low desire also travel together, and each can mask the other.
The relationship and the story you tell yourself. Conflict, resentment, mismatched expectations, and the belief that low desire is a personal failure all feed back into it. These are not "all in your head" — they are part of the same clinical picture, and they are addressable.
Most women who get a straight answer find more than one of these is in play. That is normal, and it is good news: several small, correctable contributors are usually easier to move than one imagined character flaw.
Why Cause Comes Before Treatment
The reason evaluation matters is not bureaucratic caution — it is that the right therapy depends entirely on what is driving the problem. Low-dose testosterone will not fix desire that is being suppressed by an antidepressant. A desire medication will not resolve pain that is coming from vaginal tissue changes. Treating everyone the same way is how low desire stays unsolved.
This is where a labs-first, physician-reviewed approach earns its keep. Baseline blood work — sex hormones read with an assay sensitive enough for the female range, thyroid function, prolactin, a metabolic panel, and iron studies — plus a careful review of your medications and health history turns a vague complaint into a short list of testable explanations. The lab does not make the decision; a physician reading it in the context of your symptoms does. That sequence — test, review, then treat — is what separates a plan from a guess.
The Evidence-Based Options — and Where Each Fits
Once the cause is clearer, the options are specific rather than one-size-fits-all. A few that a clinician may discuss, depending on the picture:
Address the reversible causes first. If an antidepressant, sleep debt, thyroid disease, or untreated pain is the driver, that is where treatment starts — adjusting a medication, treating the genitourinary changes of menopause with local therapy, or managing the underlying condition. Often desire improves without any desire-specific drug.
Medications approved specifically for HSDD. Two are FDA-approved for premenopausal women with acquired, generalized HSDD. Bremelanotide is an as-needed injection studied in two randomized trials of nearly 1,250 women (the RECONNECT program), where it produced a statistically significant but modest improvement in desire and a reduction in distress compared with placebo; nausea is its most common side effect (Kingsberg 2019, PMID: 31599840; FDA label 2019). Flibanserin is a daily oral option, also with a modest effect and meaningful interactions with alcohol and certain drugs. Neither is a magic answer, and honest expectation-setting is part of prescribing them.
Testosterone in the right context. The 2019 Global Consensus Position Statement — endorsed by eleven international medical societies — concluded that the one evidence-based indication for testosterone in women is HSDD, with a moderate effect, and that the strongest data are in postmenopausal women (Davis 2019, PMID: 31488288). The same statement is candid about the limits: the evidence does not support testosterone for energy, mood, cognition, or bone. Because there is no FDA-approved testosterone product for women, this is careful, physiologically dosed, off-label use that requires monitoring — not a masculinizing dose, and not a shortcut.
A note on how we handle this at the platform level: some of these therapies, including bremelanotide, are evaluated and offered only inside a physician-supervised program after an assessment — not advertised or sold off the shelf. Where an option fits your evaluation, your clinician discusses it directly with you.
What Real Monitoring Looks Like
Done well, care for low desire is a process, not a single prescription. A reasonable program looks like this: a baseline evaluation with the labs and history above; a clear hypothesis about what is driving the change; a therapy matched to that cause; and a follow-up to see whether it helped, with the willingness to adjust or stop if it did not. If testosterone is used, that means re-checking levels to keep them in the physiologic female range and watching for side effects. If a medication change is the lever, it means a real conversation with whoever manages that prescription. The measure of good care here is not a promise — it is a plan that responds to what your body and your labs actually show.
How Leader Health Approaches This
At Leader Health, low desire is treated as a clinical question with a real answer, not a topic to tiptoe around. Every patient starts with lab work and a physician-reviewed evaluation — hormones read with a female-range assay, thyroid, prolactin, and a medication and health review — so the plan follows the cause rather than a guess. Where an evidence-based therapy fits, a physician discusses it with you directly, sets honest expectations, and monitors whether it is actually helping.
The starting point is the same for everyone: a simple lab panel and a conversation with a physician who takes the concern seriously. If you have been told this is just how it is, that is the part we disagree with. Start with your lab panel and a physician review.
References
Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates (PRESIDE). Obstet Gynecol. 2008;112(5):970-978. PMID: 19008846. https://pubmed.ncbi.nlm.nih.gov/19008846/
Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/
U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31488288. https://pubmed.ncbi.nlm.nih.gov/31488288/
Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of HSDD. Mayo Clin Proc. 2018;93(4):467-487. PMID: 29545008. https://pubmed.ncbi.nlm.nih.gov/29545008/
Key takeaways
Low sexual desire is the most common sexual concern women report, and when it causes distress it is a recognized, evaluable condition — not a character flaw or an inevitable part of aging.
In most cases there is an identifiable contributor, or several: hormonal shifts, thyroid or other medical conditions, medications (antidepressants are a frequent and reversible cause), pain, sleep, mood, and relationship factors all interact.
Because the cause guides the fix, an evaluation comes before any therapy. The evidence-based options — including bremelanotide, which is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and low-dose testosterone in the postmenopausal HSDD context — each fit a specific picture, not everyone.
The practical takeaway: low desire is worth a real workup. A physician who checks labs and reviews your health and medications can usually explain what changed — and what, if anything, is worth doing about it.
If your interest in sex has faded and you cannot point to a single reason, the most useful thing to know first is this: low desire in women is common, it is usually explainable, and when it bothers you it is treatable. It is the sexual concern women report most — and when it comes with genuine distress, clinicians recognize it as a specific condition. The unhelpful part is how often it gets waved off. The useful question is not how to want it more, but what actually changed.
If you have raised this with a clinician and been told to "relax," "have a glass of wine," or "try date night," that experience is real and it is common. Those answers skip the step that matters — finding the cause. What follows is how a physician actually sorts through it.
Low Desire Is Common — and It Is a Recognized Condition
The biological and epidemiological picture is clear. In the PRESIDE study, a survey of more than 31,000 U.S. women, low desire was the single most common sexual problem, reported by roughly 38% of women; when low desire caused personal distress, it met the threshold for hypoactive sexual desire disorder (HSDD) in about 10% overall and close to 9% of women aged 18–44 (Shifren 2008, PMID: 19008846). In other words, this is not rare, and it is not a fringe complaint.
The word that does the work in that definition is distress. Desire varies enormously between people and across a lifetime, and lower desire by itself is not a disorder. What makes it a clinical issue is that it bothers you — it interferes with how you feel about yourself or your relationship. Naming it precisely matters, because a recognized condition has an evaluation pathway and evidence-based options, where a dismissed complaint has neither; the ISSWSH process of care lays out exactly that evaluation pathway (Clayton 2018). If a provider treats low desire as something to simply accept, that is information about the provider, not about whether the concern is real.
The Differential: What a Clinician Actually Checks
Desire is not a single switch. It emerges from hormones, brain chemistry, physical comfort, mood, sleep, and the relationship it lives in — which is exactly why an honest evaluation looks at several systems rather than reaching for one answer. The most common contributors:
Hormones and thyroid. Estrogen and testosterone both play a role in women's desire, and thyroid disease and elevated prolactin can blunt it; iron deficiency can contribute as well, often through the fatigue it causes. A panel that reads these together — rather than a single number — is the point.
Medications. This is the most frequently missed reversible cause. Selective serotonin reuptake inhibitors (SSRIs) and some other antidepressants commonly lower desire and delay arousal; certain hormonal contraceptives and other drugs can contribute too. Often the fix is an adjustment, a switch, or an added medication — not accepting the side effect.
Pain and the genitourinary changes of menopause. When sex is uncomfortable, desire follows the discomfort down. Vaginal dryness and tissue thinning — the genitourinary syndrome of menopause — are common, under-reported, and treatable, often with local therapy.
Sleep, stress, and mood. Chronic sleep loss and untreated depression or anxiety suppress desire directly and through fatigue. Depression and low desire also travel together, and each can mask the other.
The relationship and the story you tell yourself. Conflict, resentment, mismatched expectations, and the belief that low desire is a personal failure all feed back into it. These are not "all in your head" — they are part of the same clinical picture, and they are addressable.
Most women who get a straight answer find more than one of these is in play. That is normal, and it is good news: several small, correctable contributors are usually easier to move than one imagined character flaw.
Why Cause Comes Before Treatment
The reason evaluation matters is not bureaucratic caution — it is that the right therapy depends entirely on what is driving the problem. Low-dose testosterone will not fix desire that is being suppressed by an antidepressant. A desire medication will not resolve pain that is coming from vaginal tissue changes. Treating everyone the same way is how low desire stays unsolved.
This is where a labs-first, physician-reviewed approach earns its keep. Baseline blood work — sex hormones read with an assay sensitive enough for the female range, thyroid function, prolactin, a metabolic panel, and iron studies — plus a careful review of your medications and health history turns a vague complaint into a short list of testable explanations. The lab does not make the decision; a physician reading it in the context of your symptoms does. That sequence — test, review, then treat — is what separates a plan from a guess.
The Evidence-Based Options — and Where Each Fits
Once the cause is clearer, the options are specific rather than one-size-fits-all. A few that a clinician may discuss, depending on the picture:
Address the reversible causes first. If an antidepressant, sleep debt, thyroid disease, or untreated pain is the driver, that is where treatment starts — adjusting a medication, treating the genitourinary changes of menopause with local therapy, or managing the underlying condition. Often desire improves without any desire-specific drug.
Medications approved specifically for HSDD. Two are FDA-approved for premenopausal women with acquired, generalized HSDD. Bremelanotide is an as-needed injection studied in two randomized trials of nearly 1,250 women (the RECONNECT program), where it produced a statistically significant but modest improvement in desire and a reduction in distress compared with placebo; nausea is its most common side effect (Kingsberg 2019, PMID: 31599840; FDA label 2019). Flibanserin is a daily oral option, also with a modest effect and meaningful interactions with alcohol and certain drugs. Neither is a magic answer, and honest expectation-setting is part of prescribing them.
Testosterone in the right context. The 2019 Global Consensus Position Statement — endorsed by eleven international medical societies — concluded that the one evidence-based indication for testosterone in women is HSDD, with a moderate effect, and that the strongest data are in postmenopausal women (Davis 2019, PMID: 31488288). The same statement is candid about the limits: the evidence does not support testosterone for energy, mood, cognition, or bone. Because there is no FDA-approved testosterone product for women, this is careful, physiologically dosed, off-label use that requires monitoring — not a masculinizing dose, and not a shortcut.
A note on how we handle this at the platform level: some of these therapies, including bremelanotide, are evaluated and offered only inside a physician-supervised program after an assessment — not advertised or sold off the shelf. Where an option fits your evaluation, your clinician discusses it directly with you.
What Real Monitoring Looks Like
Done well, care for low desire is a process, not a single prescription. A reasonable program looks like this: a baseline evaluation with the labs and history above; a clear hypothesis about what is driving the change; a therapy matched to that cause; and a follow-up to see whether it helped, with the willingness to adjust or stop if it did not. If testosterone is used, that means re-checking levels to keep them in the physiologic female range and watching for side effects. If a medication change is the lever, it means a real conversation with whoever manages that prescription. The measure of good care here is not a promise — it is a plan that responds to what your body and your labs actually show.
How Leader Health Approaches This
At Leader Health, low desire is treated as a clinical question with a real answer, not a topic to tiptoe around. Every patient starts with lab work and a physician-reviewed evaluation — hormones read with a female-range assay, thyroid, prolactin, and a medication and health review — so the plan follows the cause rather than a guess. Where an evidence-based therapy fits, a physician discusses it with you directly, sets honest expectations, and monitors whether it is actually helping.
The starting point is the same for everyone: a simple lab panel and a conversation with a physician who takes the concern seriously. If you have been told this is just how it is, that is the part we disagree with. Start with your lab panel and a physician review.
References
Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates (PRESIDE). Obstet Gynecol. 2008;112(5):970-978. PMID: 19008846. https://pubmed.ncbi.nlm.nih.gov/19008846/
Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/
U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31488288. https://pubmed.ncbi.nlm.nih.gov/31488288/
Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of HSDD. Mayo Clin Proc. 2018;93(4):467-487. PMID: 29545008. https://pubmed.ncbi.nlm.nih.gov/29545008/
In this article
Frequently Asked Questions
In most cases, yes. Low desire usually has one or more identifiable contributors — hormonal, medical, medication-related, or relational — and addressing the cause often improves it. "Treatable" does not always mean a pill; sometimes it means adjusting a medication, treating pain, or improving sleep. The first step is an evaluation, not acceptance.
It can contribute, but it is rarely the whole story. Testosterone plays a role in women's desire, and low-dose testosterone has a moderate, evidence-supported effect on HSDD — mainly studied in postmenopausal women. But desire also depends on estrogen, thyroid function, medications, mood, sleep, and comfort, which is why testing comes before assuming hormones are the cause.
Yes. Two medications are FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder: bremelanotide (an as-needed injection) and flibanserin (a daily oral medication). Both have modest effects and specific side-effect profiles, so they suit some women and not others. Where one is appropriate, it is used only inside a physician-supervised program after an evaluation — not sold off the shelf — and a physician can help judge fit.
Antidepressant-related low desire is common and often reversible. Do not stop the medication on your own. Options a clinician may consider include adjusting the dose, switching to an antidepressant less likely to affect desire, or adding a second medication that can offset the effect. This is a conversation to have with whoever manages that prescription.
Usually both, in some proportion — and that is not a contradiction. Hormones, medications, and health conditions shape the biology; stress, mood, and the relationship shape the context. A good evaluation looks at both rather than forcing a single explanation, because the mix is different for each person.
A thorough remote evaluation combines a detailed history and symptom review with baseline lab work drawn locally, then a physician reviews the results with you before any therapy is considered. The privacy of an online visit is, for many women, easier than raising the topic in a rushed in-person appointment.
About Medical Reviewer
About Medical Reviewer
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD, MBA
CMO of Leader Health
All related stories post
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
Hormone Therapy
Sexual health
Weight Loss & Longevity
Diagnostic Labs
Company
Take Action
More From Leader
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION